Sinphar Pharmaceutical Co. Ltd.
TTWSE:173430.70
TWD
0.00
(0.00%)
Sinphar Pharmaceutical Co. Ltd.
TWSE:1734
(Taiwan Stock Exchange)
Recent
price
30.70
P/E
ratio
18.38
div
yld
- -
ROIC.AI
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.- Similar Companies
- Business
- Sinphar Pharmaceutical Co., Ltd. researches, develops, manufactures, and markets pharmaceuticals, health supplements, medical cosmetics, and related products. The company produces anti-cancer drugs including injections, solid preparations, and hormone reagents; therapeutic pharmaceuticals covering antineoplastic agents, ophthalmic solutions, ear-nose-throat treatments, oral medications, respiratory drugs, dermatology products, analgesics and non-steroidal anti-inflammatory drugs, metabolic and nutritional supplements, gastrointestinal remedies, and others; functional foods and nutrients under brands such as Sinphar, DailyCare, Migus, YouBest, and SynCoreBio; cosmetics including shampoos, body washes, tonics, lotions, moisturizers, sunscreens, serums, anti-aging creams, and repair essences under brands like DYNASKIN and Yestuner; plant extracts; and pharmaceutical packaging such as eye drop bottles, vials, tablet containers, and medical-grade plastics. It operates through pharmaceuticals, healthy food, and other segments, provides OEM services encompassing product design, testing, development, and manufacturing, and maintains approximately 1,300 shop-in-shop branches across Taiwan as the largest specialized pharmacy network in the market. Sinphar Pharmaceutical Co., Ltd. conducts business in Taiwan, Mainland China, Vietnam, Indonesia, and internationally, with subsidiaries including SynCore Biotechnology for oncology R&D, ZuniMed Biotech for medical devices and packaging with ISO15378 Class 100,000 clean rooms, and Sinphar Tianli Pharmaceutical for phytonutrients, traditional Chinese medicines, and functional ingredients. Founded in 1977 and headquartered at No. 84, Zhongshan Road, Yilan City, Taiwan, the company pursues smart manufacturing, digitalization, and capacity expansions in oncology injectables with automated isolators and closed systems. Recent developments encompass new product launches anticipated in 2025 including one therapeutic drug for mild eczema and seborrheic dermatitis, four functional supplements for male health, blood sugar regulation, intestinal health, and throat health, alongside strategic collaborations with Japanese firms for co-development, manufacturing, and market entry in ASEAN regions; introductions of Japanese gastrointestinal and hypolipidemic drugs; API advancements with licenses for sulfamethoxazole and mesulphen; deepened alliances with subsidiaries for R&D sharing, such as freeze-drying processes with SynCore and patented health foods with Tianli; and ongoing Phase III trials for projects like SB05PC in pancreatic cancer across multiple countries with MOEA funding.